JP2020124212A5 - - Google Patents

Download PDF

Info

Publication number
JP2020124212A5
JP2020124212A5 JP2020076805A JP2020076805A JP2020124212A5 JP 2020124212 A5 JP2020124212 A5 JP 2020124212A5 JP 2020076805 A JP2020076805 A JP 2020076805A JP 2020076805 A JP2020076805 A JP 2020076805A JP 2020124212 A5 JP2020124212 A5 JP 2020124212A5
Authority
JP
Japan
Prior art keywords
hematopoietic cells
specific amount
enlarged
nucleic acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020076805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020124212A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020124212A publication Critical patent/JP2020124212A/ja
Publication of JP2020124212A5 publication Critical patent/JP2020124212A5/ja
Priority to JP2022085669A priority Critical patent/JP2022113722A/ja
Withdrawn legal-status Critical Current

Links

JP2020076805A 2014-03-26 2020-04-23 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法 Withdrawn JP2020124212A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022085669A JP2022113722A (ja) 2014-03-26 2022-05-26 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461970787P 2014-03-26 2014-03-26
US61/970,787 2014-03-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016559216A Division JP2017511132A (ja) 2014-03-26 2015-03-25 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022085669A Division JP2022113722A (ja) 2014-03-26 2022-05-26 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2020124212A JP2020124212A (ja) 2020-08-20
JP2020124212A5 true JP2020124212A5 (https=) 2020-10-01

Family

ID=54196365

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016559216A Pending JP2017511132A (ja) 2014-03-26 2015-03-25 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法
JP2020076805A Withdrawn JP2020124212A (ja) 2014-03-26 2020-04-23 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法
JP2022085669A Pending JP2022113722A (ja) 2014-03-26 2022-05-26 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016559216A Pending JP2017511132A (ja) 2014-03-26 2015-03-25 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022085669A Pending JP2022113722A (ja) 2014-03-26 2022-05-26 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法

Country Status (5)

Country Link
US (2) US20170173083A1 (https=)
EP (2) EP3122181A4 (https=)
JP (3) JP2017511132A (https=)
CN (2) CN106455542A (https=)
WO (1) WO2015148716A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170173083A1 (en) * 2014-03-26 2017-06-22 The Brigham And Women's Hospital, Inc. Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells
WO2015172149A1 (en) 2014-05-09 2015-11-12 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
AU2016261358B2 (en) 2015-05-11 2021-09-16 Editas Medicine, Inc. Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells
EP3307887A1 (en) 2015-06-09 2018-04-18 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CN105238758A (zh) * 2015-09-17 2016-01-13 中国科学院广州生物医药与健康研究院 一种体外获得造血干/祖细胞的方法
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
WO2017161001A1 (en) * 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CA3024273A1 (en) * 2016-06-01 2017-12-07 Universite De Montreal Selection of human hematopoetic stem cells using epcr
CN106119204A (zh) * 2016-06-20 2016-11-16 何力丰 一种可用于干细胞和基因治疗的改造细胞的基因技术
KR102522572B1 (ko) * 2016-08-18 2023-04-17 내셔널 유니버시티 오브 싱가포르 조혈 줄기 및 전구 세포의 생성, 증식 및 분화를 위한 치환된 아졸 유도체
WO2018203855A2 (en) 2016-11-16 2018-11-08 Yedi̇tepe Üni̇versi̇tesi̇ A combination inhibiting meis proteins
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CN109706119B (zh) * 2018-04-13 2020-11-27 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109207427B (zh) * 2018-09-17 2020-12-08 诺未科技（银川）有限公司 一种将人造血祖细胞转变为造血干细胞的方法
CN110799641B (zh) * 2018-04-13 2021-02-19 诺未科技（北京）有限公司 丁酸钠的用途及含有丁酸钠的培养体系
US20210214699A1 (en) * 2018-07-05 2021-07-15 Lempo Therapeutics Ltd Methods and compositions for modulating myeloperoxidase (mpo) expression
IL260445B (en) * 2018-07-05 2019-08-29 Lempo Therapeutics Ltd Methods and compositions for modulating myeloperoxidase (mpo) expression
CN109593714A (zh) * 2018-12-28 2019-04-09 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109207426B (zh) * 2018-09-17 2020-08-21 诺未科技（北京）有限公司 一种将人造血祖细胞转变为造血干细胞的方法
WO2020057107A1 (zh) * 2018-09-17 2020-03-26 诺未科技（北京）有限公司 一种组合物及其用途
CN109593715B (zh) * 2018-12-28 2020-12-08 北京承诺未来科技有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109536447A (zh) * 2018-12-28 2019-03-29 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109609455A (zh) * 2018-12-28 2019-04-12 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109593716B (zh) * 2018-12-28 2021-04-09 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN110592017B (zh) * 2019-07-12 2021-02-19 中国医学科学院血液病医院(中国医学科学院血液学研究所) 组蛋白甲基转移酶抑制剂在制备促进巨核细胞增殖或血小板产生的产品中的用途
AU2020407664A1 (en) 2019-12-20 2022-08-18 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
EP4326263A1 (en) 2021-04-23 2024-02-28 Tenaya Therapeutics, Inc. Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy
AU2022270657A1 (en) 2021-05-04 2023-11-16 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
CN114958744A (zh) * 2022-07-12 2022-08-30 上海派思维新生物医药科技有限公司 一种离体干细胞扩大培养方法和应用
CN120769905A (zh) 2023-01-20 2025-10-10 国立大学法人熊本大学 培养基、制造方法、及细胞制剂
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE10002643A1 (de) * 2000-01-21 2001-07-26 Cognis Deutschland Gmbh Desodorierende Zubereitungen
AU2003295444A1 (en) * 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
EP2023912A2 (en) * 2006-05-26 2009-02-18 Celgene Corporation Methods and compositions using immunomodulatory compounds in combination therapy
CA2745073A1 (en) * 2008-12-03 2010-06-10 Li-Huei Tsai Inhibition of hdac2 to promote memory
PT2760994T (pt) * 2011-09-30 2017-08-24 Bluebird Bio Inc Compostos para melhor transdução viral
US20130136722A1 (en) * 2011-11-11 2013-05-30 The Board Of Trustees Of The University Of Illinois Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts
RU2650811C2 (ru) * 2012-02-24 2018-04-17 Фред Хатчинсон Кэнсер Рисерч Сентер Композиции и способы лечения гемоглобинопатии
DK3444342T3 (da) * 2012-07-11 2020-08-24 Sangamo Therapeutics Inc Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
SI2890780T1 (sl) * 2012-08-29 2020-11-30 Sangamo Therapeutics, Inc. Postopki in sestavki za zdravljenje genetskega stanja
US20170173083A1 (en) * 2014-03-26 2017-06-22 The Brigham And Women's Hospital, Inc. Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells

Similar Documents

Publication Publication Date Title
JP2020124212A5 (https=)
US20240002843A1 (en) Compositions and methods for the treatment of hemoglobinopathies
US20230118337A1 (en) Compositions and methods for the treatment of hemoglobinopathies
Jung et al. Reprogram or reboot: small molecule approaches for the production of induced pluripotent stem cells and direct cell reprogramming
JP6525963B2 (ja) 血液疾患を治療するための、濃縮されかつ増殖したヒト臍帯血幹細胞
JP2019516754A5 (https=)
Wang et al. CRISPR/Cas9-mediated mutagenesis at microhomologous regions of human mitochondrial genome
Xu et al. Therapeutic application of endothelial progenitor cells for treatment of cardiovascular diseases
JP7558814B2 (ja) 遺伝子治療
CN109475582A (zh) 基因递送的改进方法
JPWO2021228944A5 (https=)
JPWO2023066735A5 (https=)
CN115087455A (zh) 用于治疗或预防克罗恩病的组合物和方法
AU2021324891A9 (en) Compositions and methods for treating or preventing hereditary angioedema
Taebi et al. Genetic engineering in hematopoietic stem cells for β-Hemoglobinopathies treatment: advances, challenges, and clinical translation
JP2005514071A5 (https=)
US20250223562A1 (en) IMMUNOSELECTED UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS (UC-MSCs) AND DOWNSTREAM BIOLOGICS
JP7851081B2 (ja) 異常ヘモグロビン症の治療用組成物および方法
Maalaoui Characterization of the UM171-Graft: Dissecting the lymphoid lineage potential of the UM171-Graft
Nasser et al. Rejuvenation and Regenerative Potential of Heart Stem Cells
HK40080440A (en) Compositions and methods for the treatment of hemoglobinopathies
Mountford et al. Stem cell biology and the cardiovascular system
JPWO2023108136A5 (https=)
BR122025008935A2 (pt) Molécula de grna, método para alteração de uma célula-tronco hematopoiética (hsc) ou uma célula progenitora hematopoiética (hpc), composição, usos das mesmas, e método para preparação de uma célula- tronco hematopoiética (hsc) ou uma célula progenitora hematopoiética (hpc)
Shrestha Mechanism of Human Hematopoietic Stem Cell Loss During Ex Vivo Manipulation and Gene Transfer